CLOUDBREAK PHARMA INC.
撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (3) CHANGE OF COMPOSITION OF BOARD COMMITTEES

The board (the "**Board**") of directors (the "**Directors**") of Cloudbreak Pharma Inc. (the "**Company**"; together with its subsidiaries, the "**Group**") hereby announces that:

1. Mr. LIU Chung Mun (廖仲敏) ("**Mr. Liu**") has tendered his resignation as an independent non-executive Director ("**INED**"), the chairman of the audit committee of the Company (the "**Audit Committee**"), a member of the remuneration committee of the Company (the "**Remuneration Committee**") and a member of the nomination committee of the Company (the "**Nomination Committee**"; together with the Audit Committee and the Remuneration Committee, the "**Board Committees**") with effect from 2 October 2025;

2. Mr. MA Yiu Ho Peter (馬遙豪) ("**Mr. Ma**") will be appointed as an INED, the chairman of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee with effect from 2 October 2025; and

3. Dr. LI Jun Zhi ("**Dr. Li**"), a non-executive Director, will be appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee with effect from 2 October 2025.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Liu has tendered his resignation as an INED, the chairman of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee with effect from 2 October 2025 in order to devote more time to his family and other commitments.

Mr. Liu has confirmed that: (i) he has no disagreement with the Board; and (ii) there is no other matter that needs to be brought to the attention of the shareholders of the Company in respect of his said resignation. The Board would like to express its gratitude to Mr. Liu for his services to the Company during his tenure.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Ma will be appointed as an INED, the chairman of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee with effect from 2 October 2025.

The biographical details of Mr. Ma are as follows:

Mr. Ma, aged 60, holder of a degree in Master of Business Administration, possesses over 30 years of experience in the finance and accounting fields. He is a member of the Hong Kong Institute of Certified Public Accountants, a fellow member of the Association of Chartered Certified Accountants (formerly known as Chartered Association of Certified Accountants) and a member of the Hong Kong Institute of Directors. Currently, Mr. Ma serves as the financial controller of Chyau Fwu Properties Limited, a company principally engaged in property development and hospitality in Hong Kong and Asia. Previously, Mr. Ma has also served as financial controller and company secretary of Joy City Property Limited (formerly known as The Hong Kong Parkview Group Limited) (stock code: 207) and as financial controller of V1 Group Limited (formerly known as VODone Limited) (stock code: 82) and Renewable Energy Asia Group Limited (formerly known as Superior Fastening Technology Limited and delisted on 7 February 2020, with former stock code of SGX:5DW). In addition, Mr. Ma has served as an independent non-executive director of a number of companies listed on the Stock Exchange, including, without limitation, Indigo Star Holdings Limited (stock code: 8373) from October 2017 to May 2024 and Jin Mi Fang Group Holdings Limited (formerly known as Royal Group Holdings International Company Limited) (stock code: 8300) from July 2016 to November 2023.

Mr. Ma has entered into a letter of appointment (the "**Letter of Appointment**") with the Company in relation to his appointment as an INED for an initial term of three years commencing from 2 October 2025, unless terminated by not less than thirty days' prior notice in writing served by either party. Mr. Ma is entitled to a remuneration of US$30,000 per annum, payable semi-annually in two equal instalments on or before the last day of each of the sixth month and the twelfth month of each financial year of the Company. Save as aforesaid, Mr. Ma is not entitled to any other remuneration under the Letter of Appointment. The aforesaid remuneration of Mr. Ma has been determined having regard to his experience, duties and responsibilities, the recommendation of the Remuneration Committee as well as the prevailing market conditions, and will be reviewed by the Remuneration Committee and the Board on an annual basis having regard to the operating results of the Group and Mr. Ma's performance of his duties. Mr. Ma's appointment is subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company.

Save as disclosed hereinabove, as at the date of this announcement, Mr. Ma: (i) does not have any interests and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other position within the Company or any other company within the Group; (iii) does not at present and did not in the last three years immediately preceding the date of his appointment hold any directorship in any other public companies the securities of which are listed on the Stock Exchange or any other securities market whether within or outside Hong Kong; and (iv) does not have any relationship with any other Directors, members of senior management, substantial shareholders or controlling shareholders (each as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company.

Mr. Ma has confirmed to the Company his independence as regards each of the factors referred to in Rule 3.13 of the Listing Rules and that: (i) he does not have any past or present financial or other interests in the business of the Group or any connection with any of the core connected persons (as defined in the Listing Rules) of the Company; and (ii) there are no other factors which affect or may affect his independence at the time of his appointment.

Save as disclosed hereinabove, there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to the appointment of Mr. Ma and there is no other information required to be disclosed pursuant to the requirements under Rule 13.51(2) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. Ma for his appointment as an INED of the Company.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

In addition to the appointment of Mr. Ma as the chairman of the Audit Committee and a member of each of the Remuneration Committee and the Nomination Committee in place of Mr. Liu following the resignation of Mr. Liu from the said positions as mentioned hereinabove, Dr. Li, an existing non-executive Director, will be appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee with effect from 2 October 2025.

The biographical details of Dr. Li are set out in the prospectus issued by the Company on 24 June 2025 (the "**Prospectus**"). To the best of the knowledge, information and belief of the Board, as at the date of this announcement, there have been no material changes to the biographical details of Dr. Li as stated in the Prospectus.

The Board would like to take this opportunity to congratulate Dr. Li on his new appointments to the Board Committees.

Immediately following the above-mentioned changes to the composition of the Board Committees, each of the Board Committees will comprise four members, as follows:

(a) the Audit Committee will comprise Mr. Ma as the chairman and Mr. LAI, Hin Wing Henry Stephen (賴顯榮) ("**Mr. Lai**"), Ms. NIE Sijiang (聶四江) ("**Ms. Nie**") and Dr. Li as members;

(b) the Remuneration Committee will comprise Ms. Nie as chairlady and Mr. Lai, Dr. Li and Mr. Ma as members; and

(c) the Nomination Committee will comprise Mr. Lai as chairman and Ms. Nie, Dr. Li and Mr. Ma as members.

By Order of the Board
Cloudbreak Pharma Inc.
Dr. NI Jinsong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 30 September 2025

As at the date of this announcement, Board comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong as executive Directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive Directors; and (iii) Mr. Lai Hin Wing Henry Stephen, Mr. Liu Chung Mun and Ms. Nie Sijiang as independent non-executive Directors.

* *For identification purpose only*